Tocoretinate inhibited the contraction of collagen gel matrices by human dermal fibroblasts with tenascin-C expression

Journal of Dermatological Science

Volumn 22, Issue 1, 1999, Pages 45-53

  Yamada, Eigo ^a   Mizutani, Hitoshi ^a   Yoshida, Toshimichi ^a   Isoda, Ken ichi ^a   Shimizu, Masayuki ^a  

^a MIE UNIVERSITY   (Japan)

Author keywords

Matrix; Retinoid; Scleroderma; Tension

Indexed keywords

COLLAGEN GEL; COLLAGEN TYPE 1; ISOTRETINOIN; RETINOIC ACID; TENASCIN; TOCORETINATE;

ACNE; ARTICLE; CONTROLLED STUDY; DERMIS; DRUG MECHANISM; EXTRACELLULAR MATRIX; HUMAN; HUMAN CELL; KELOID; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; SCLERODERMA; SKIN FIBROBLAST; SKIN ULCER; TENSILE STRENGTH;

CELLS, CULTURED; COLLAGEN; DRUG COMBINATIONS; EXTRACELLULAR MATRIX; FIBROBLASTS; HUMANS; SKIN; TENASCIN; TRETINOIN; VITAMIN E;

EID: 0032713559     PISSN: 09231811     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0923-1811(99)00047-X     Document Type: Article

References (34)

1. Dicken C.H. Retinoids: a review. J. Am. Acad. Dermatol. 11:1984;541-552.
2. Orfanos C.E., Ehlert R., Gollnick H. The retinoids. A review of their clinical pharmacology and therapeutic use. Drugs. 34:1987;459-503.
3. Lowe N.J. Topical retinoids: in vivo predictive assays. J. Am. Acad. Dermatol. 15:1986;766-772.
4. Kligman A.M. Guidelines for the use of topical tretinoin (Retin-A) for photoaged skin. J. Am. Acad. Dermatol. 21:1989;650-654.
5. Tong P.S., Horowitz N.N., Wheeler L.A. Trans retinoic acid enhances the growth response of epidermal keratinocytes to epidermal growth factor and transforming growth factor beta. J. Invest. Dermatol. 94:1990;126-131.
6. Kim R.Y., Stern W.H. Retinoids and butyrate modulate fibroblast growth and contraction of collagen matrices. Invest. Ophthal. Vis. Sci. 31:1990;1183-1186.
7. Ohta A., Uitto J. Procollagen gene expression by scleroderma fibroblasts in culture. Inhibition of collagen production and reduction of pro alpha 1(I) and pro alpha 1(III) collagen messenger RNA steady-state levels by retinoids. Arthritis Rheum. 30:1987;404-411.
8. Meisler N.T., Parrelli J., Gendimenico G.J., Mezick J.A., Cutroneo K.R. All-trans-retinoic acid inhibition of Pro alpha 1(I) collagen gene expression in fetal rat skin fibroblasts: identification of a retinoic acid response element in the Pro alpha 1(I) collagen gene. J. Invest. Dermatol. 108:1997;476-481.
9. Abergel R.P., Meeker C.A., Oikarinen H., Oikarinen A.I., Uitto J. Retinoid modulation of connective tissue metabolism in keloid fibroblast cultures. Arch. Dermatol. 121:1985;632-635.
10. Delany A.M., Brinckerhoff C.E. The synthetic retinoid (4-hydroxyphenyl)retinamide decreases collagen expression in vitro and in the tight-skin mouse. Arthritis Rheum. 36:1993;983-993.
11. Maurice P.D., Bunker C.B., Dowd P.M. Isotretinoin in the treatment of systemic sclerosis. Br. J. Dermatol. 121:1989;367-374.
12. Uhlmann A., Brauninger W. Therapeutic results with the aromatic retinoid (Tigason) in Sharp syndrome and progressive scleroderma. Z. Hautkr. 60:1985;774-776.
13. Bahmer F.A., Zaun H. Isotretinoin therapy for progressive systemic sclerosis. Arch. Dermatol. 121:1985;308.
14. Daly TJ, GL E, GL, L. WW. A double-blind placebo-controlled efficacy study of tretinoin cream 0.05% in the treatment of keloids and hypertrophic scars. Clin Res 1986;34:744A.
15. Anzai T. Tocoretinate. Clin. Drug Ther. 12:1993;144.
16. Kawamura N., Miki K., Kurokawa K., Kojima I. Enhancement by tocoretinate of epidermal growth factor-induced DNA synthesis in human intestinal epithelial cells. Digest. Dis. Sci. 39:1994;2191-2196.
17. Sakyo K., Otsuka N., Hamada H. et al. Effect of tocoretinate on migration of normal human skin fibroblasts. Pharmacometrics. 43:1992;103-110.
18. Nakazawa T., Kuroda T., Arai I. et al. Metabolic fate of tocoretinate (1), distribution of C-14 Tocoretinate in rats and dogs. Pharmacometrics. 43:1992;205-210.
19. Mizutani H., Yoshida T., Nouchi N., Shimizu M. Topical tocoretinate improved hypertrophic scar, skin sclerosis in systemic sclerosis and morphea. J. Dermatol. 26:1999;11-17.
20. Chiquet-Ehrismann R., Mackie E.J., Pearson C.A., Sakakura T. Tenascin: an extracellular matrix protein involved in tissue interactions during fetal development and oncogenesis. Cell. 47:1986;131-139.
21. Lacour J.P., Vitetta A., Chiquet-Ehrismann R., Pisani A., Ortonne J.P. Increased expression of tenascin in the dermis in scleroderma. Br. J. Dermatol. 127:1992;328-334.
22. Hashimoto K. Overexpression of tenascin in scleroderma skin. Mie. Med. J. 41:1991;31-39.
23. Latijnhouwers M.A., Bergers M., Van Bergen B.H., Spruijt K.I., Andriessen M.P., Schalkwijk J. Tenascin expression during wound healing in human skin. J. Pathol. 178:1996;30-35.
24. Kusagawa H., Onoda K., Namikawa S., Yada I., Okada A., Yoshida T., Sakakura T. Expression and degeneration of tenascin-C in human lung cancers. Br. J. Cancer. 77:1998;98-102.
25. Tucker R.P., Brunso-Bechtold J.K., Jenrath D.A., Khan N.A., Poss P.M., Sweatt A.J., Xu Y. Cellular origins of tenascin in the developing nervous system. Perspect. Dev. Neurobiol. 2:1994;89-99.
26. Murphy-Ullrich J.E., Lightner V.A., Aukhil I., Yan Y.Z., Erickson H.P., Hook M. Focal adhesion integrity is downregulated by the alternatively spliced domain of human tenascin. J. Cell. Biol. 115:1991;1127-1136.
27. Nakao N., Hiraiwa N., Yoshiki A., Ike F., Kusakabe M. Tenascin-C promotes healing of Habu-snake venom-induced glomerulonephritis: studies in knockout congenic mice and in culture. Am. J. Pathol. 152:1998;1237-1245.
28. Schiro J.A., Chan B.M., Roswit W.T., Kassner P.D., Pentland A.P., Hemler M.E., Eisen A.Z., Kupper T.S. Integrin alpha 2 beta 1 (VLA-2) mediates reorganization and contraction of collagen matrices by human cells. Cell. 67:1991;403-410.
29. Yoshida H., Fujita S., Iizuka T., Yoshida T., Sakakura T. The specific expression of tenascin in the synovial membrane of the temporomandibular joint with internal derangement: an immunohistochemical study. Histochem. Cell. Biol. 107:1997;479-484.
30. Kono T., Tanii T., Furukawa M., Mizuno N., Taniguchi S., Ishii M., Hamada T., Yoshizato K. Effect of tretinoin on collagen gel contraction induced by mouse 3T3 fibroblasts. J. Dermatol. Sci. 2:1991;45-49.
31. Savoia P., Novelli M., De Matteis A., Verrone A., Bernengo M.G. Effects of topical calcipotriol on the expression of adhesion molecules in psoriasis. J. Cutaneous Pathol. 25:1998;89-94.
32. Oberhauser A.F., Marszalek P.E., Erickson H.P., Fernandez J.M. The molecular elasticity of the extracellular matrix protein tenascin. Nature. 393:1998;181-185.
33. Imai K., Kusakabe M., Sakakura T., Nakanishi I., Okada Y. Susceptibility of tenascin to degradation by matrix metalloproteinases and serine proteinases. FEBS Lett. 352:1994;216-218.
34. Guerin E., Ludwig M.G., Basset P., Anglard P. Stromelysin-3 induction and interstitial collagenase repression by retinoic acid. Therapeutical implication of receptor-selective retinoids dissociating transactivation and AP-1-mediated transrepression. J. Biol. Chem. 272:1997;11088-11095.